Intrinsic brain functional connectivity predicts treatment-related motor complications in drug-naive Parkinson’s disease patients
Objective: Using resting-state functional MRI, we investigated intrinsic brain networks connectivity at baseline in a cohort of drug-naïve Parkinson’s disease (PD) patients which successively developed treatment-related…Opicapone in fluctuating Parkinson’s disease: The daily clinical practice
Objective: To evaluate the effectiveness, tolerability and safety of opicapone as add-on to levodopa (LD) in the daily clinical practice in fluctuating Parkinson’s disease (PD)…Home videos made on smart phone supplements paper based diary for correct identification of Motor states in Parkinson’s disease
Objective: We aimed to assess the feasibility of home videos made on smart phone as a supplemental tool to paper based diary in registering the…Altered interhemispheric synchrony in Parkinson’s disease patients with levodopa-induced dyskinesias
Objective: Our investigation aimed to explore interhemispheric functional alterations and its corresponding morphological synchronization changes. Background: Levodopa-induced dyskinesias are common motor complication of Parkinson’s disease…Combined therapy VS only levodopa therapy in a 5-years follow up cohort
Objective: Describe the frequencies of appearance of motor fluctuations, impulse control disorders, in two therapeutic regimes: combined therapy (levodopa plus an other antiparkinsonian drug) or…Real-World Evidence for a Smartwatch-based Parkinson’s Motor Assessment App in Patients Undergoing Therapy Changes
Objective: We sought to investigate patient and clinician usability of a smartwatch-based wearable motor assessment system for measuring Parkinson’s disease (PD) motor symptoms in patients undergoing…Analysis of the Shape of the Gocovri Steady-state PK Profile: Implications for an Extended Release Product
Objective: To demonstrate the unique shape and pharmacokinetic (PK) profile of Gocovri® (amantadine) extended release (ER) capsules by using metrics pertinent to ER dosage forms.…The effect of ADORA2A gene polymorphism on the dyskinesia of Parkinson’s Disease
Objective: To investigate the relationship of levodopa-induced dyskinesia with ADORA2A gene polymorphisms in PD patients. Background: With the progression of the disease, motor complications and…Dyskinesia Rates in Patients with Parkinson’s Disease on CVT-301 (levodopa inhalation powder)
Objective: Analysis of dyskinesia as reported by PD diary, adverse events, UPDRS part IV dyskinesia score and examiner rated observation, during a phase 3 study…Comparing motor and neuropathological features of Parkinson’s disease dementia and dementia with Lewy bodies
Objective: To compare motor and neuropathological features of Parkinson’s disease dementia (PDD) and dementia with Lewy bodies (DLB) and to determine clinical and neuropathological differences…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 49
- Next Page »